Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.48 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.37 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.37 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 6/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112533 | 0.92 | PGR (0.48) | PGRPFKFB2PFKFB1PFKFB3AR | |
| SCHEMBL4962255 | 0.89 | MRGPRX4 (0.40) | PGRARMRGPRX4FFAR4USP30 | |
| SCHEMBL4104566 | 0.87 | PGR (0.46) | PGRPFKFB2PFKFB1PFKFB3RAB9A | |
| SCHEMBL4108130 | 0.86 | PGR (0.64) | PGRPFKFB2PFKFB1PFKFB3RAB9A | |
| SCHEMBL4109845 | 0.85 | PGR (0.44) | PGRPFKFB2PFKFB1PFKFB3AR | |
| SCHEMBL4976120 | 0.82 | PGR (0.46) | PGRARMRGPRX4FFAR4 | |
| SCHEMBL4106340 | 0.81 | PGR (0.47) | PGRPFKFB2PFKFB1PFKFB3AR | |
| SCHEMBL4959655 | 0.81 | MRGPRX4 (0.39) | PGRARMRGPRX4FFAR4USP30 | |
| SCHEMBL4110197 | 0.79 | PGR (0.45) | PGRAR | |
| SCHEMBL4107682 | 0.79 | PGR (0.46) | PGRPFKFB2PFKFB1PFKFB3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060241125-A1 | Compounds useful in therapy | BRADLEY PAUL A | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241125-A1 | Compounds useful in therapy | CBR3, GPER1, CBR1 | PGR 57/4885PFKFB2 3929/4885PFKFB1 3798/4885 |
| US-20090099209-A1 | Compounds Useful in Therapy | CBR3, CBR1, GPER1 | PGR 87/4885PFKFB2 3718/4885PFKFB1 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.